COLLINS HELEN LOUISE (CHIEF MEDICAL OFFICER) sold 16.7% of their position (5K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $219.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 6/22/2026ACC: 0001701247-26-000010
Officer· CHIEF MEDICAL OFFICER
Since Feb 2026
-5K
Net shares
Net seller
$219.0K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
5K acquired · 10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+5K
Price / share
$2.48
Trade value
$12.40K
% of position
20.0%
6/17/2026
25K→30K
Common Stock
Direct
Shares
−1.27K
Price / share
$42.83
Trade value
$54.30K
% of position
4.2%
6/17/2026
30K→28.73K
Common Stock
Direct
Shares
−2.60K
Price / share
$43.87
Trade value
$114.02K
% of position
9.0%
6/17/2026
28.73K→26.13K
Common Stock
Direct
Shares
−1.13K
Price / share
$44.74
Trade value
$50.69K
% of position
4.3%
6/17/2026
26.13K→25K
Total
Net shares
+0.00
Net value
-$206.62K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/17/2026 | M · Option Exercise | +5K | $2.48 | $12.40K | 20.0% | 25K | 30K |
| Common Stock Direct | 6/17/2026 | S · Sale | −1.27K | $42.83 | $54.30K | 4.2% | 30K | 28.73K |
| Common Stock Direct | 6/17/2026 | S · Sale | −2.60K | $43.87 | $114.02K | 9.0% | 28.73K | 26.13K |
| Common Stock Direct | 6/17/2026 | S · Sale | −1.13K | $44.74 | $50.69K | 4.3% | 26.13K | 25K |
| Total | +0.00 | -$206.62K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
5K shares
Shares
−5K
Strike price
2.48
Held after
121.27K
Exercisable
—
6/17/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock5K shares | 6/17/2026 | M · Option Exercise | −5K | 2.48 | — | 121.27K |